Current and experimental treatments of Parkinson disease: A guide for neuroscientists

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 325-337

  Oertel, Wolfgang ^a,b   Schulz, Jörg B ^c,d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b National Institute for Environment and Health   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

60th Anniversary of the Journal of Neurochemistry; clinical therapeutics; dopamine; movement disorders; neurodegenerative diseases; Parkinson disease

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ELTOPRAZINE; ENTACAPONE; ISTRADEFYLLINE; LEVODOPA; LISURIDE; MAVOGLURANT; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OPICAPONE; PERGOLIDE; PIOGLITAZONE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; PRELADENANT; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; TOLCAPONE; TOZADENANT; UNINDEXED DRUG;

BRAIN DEPTH STIMULATION; DAYTIME SOMNOLENCE; DIETARY INTAKE; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DYSKINESIA; GLOBUS PALLIDUS; HEART MUSCLE FIBROSIS; HUMAN; IMPULSE CONTROL DISORDER; LEG EDEMA; LUNG FIBROSIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC INTOLERANCE; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SPEECH THERAPY; SUBTHALAMIC NUCLEUS; THALAMOTOMY;

EID: 84991235427     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13750     Document Type: Review

References (84)

1. Aarsland D., Laake K., Larsen J. P. and Janvin C. (2002) Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 72, 708–712.
2. Adler C. H., Sethi K. D., Hauser R. A., Davis T. L., Hammerstad J. P., Bertoni J., Taylor R. L., Sanchez-Ramos J. and O'Brien C. F. (1997) Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49, 393–399.
3. Allam M. F., Campbell M. J., Del Castillo A. S. and Fernandez-Crehuet Navajas R. (2004) Parkinson's disease protects against smoking? Behav. Neurol. 15, 65–71.
4. Angot E., Steiner J. A., Hansen C., Li J.-Y. and Brundin P. (2010) Are synucleinopathies prion-like disorders? Lancet Neurol. 9, 1128–1138.
5. Ascherio A., LeWitt P. A., Xu K. et al. (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66, 1460–1468.
6. Beal M. F., Oakes D., Shoulson I. et al. (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71, 543–552.
7. Berg D., Postuma R. B., Adler C. H. et al. (2015) MDS research criteria for prodromal Parkinson's disease. Mov. Disord. 30, 1600–1611.
8. Bhattacharyya S., Bakshi R., Logan R., Ascherio A., Macklin E. A. and Schwarzschild M. A. (2016) Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Mov. Disord. 31, 417–421.
9. Burn D., Emre M., McKeith I., De Deyn P. P., Aarsland D., Hsu C. and Lane R. (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov. Disord. 21, 1899–1907.
10. Cilia R., Akpalu A., Sarfo F. S. et al. (2014) The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 137, 2731–2742.
11. Clemens P., Baron J. A., Coffey D. and Reeves A. (1995) The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology 117, 253–256.
12. Costa J., Lunet N., Santos C., Santos J. and Vaz-Carneiro A. (2010) Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J. Alzheimers Dis. 20 Suppl 1, S221–S238.
13. Dasgupta P., Kinkade R., Joshi B., Decook C., Haura E. and Chellappan S. (2006) Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc. Natl Acad. Sci. USA 103, 6332–6337.
14. Deuschl G., Schade-Brittinger C., Krack P. et al. (2006) A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 355, 896–908.
15. Deuschl G., Schüpbach M., Knudsen K., Pinsker M. O., Cornu P., Rau J., Agid Y. and Schade-Brittinger C. (2013) Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat. Disord. 19, 56–61.
16. Donadio V., Incensi A., Piccinini C., Cortelli P., Giannoccaro M. P., Baruzzi A. and Liguori R. (2015) Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease. Ann. Neurol. 79, 306–316.
17. Doppler K., Ebert S., Uçeyler N., Trenkwalder C., Ebentheuer J., Volkmann J. and Sommer C. (2014) Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol. 128, 99–109.
18. Evans A. H., Lawrence A. D., Potts J., MacGregor L., Katzenschlager R., Shaw K., Zijlmans J. and Lees A. J. (2006) Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 77, 317–321.
19. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C. W., Tanner C. and Marek K. (2004) Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498–2508.
20. Fox S. H., Katzenschlager R., Lim S. Y. et al. (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26(Suppl 3), S2–S41.
21. Goedert M., Spillantini M. G., Del Tredici K. and Braak H. (2013) 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24.
22. Gong L., Zhang Q. L., Zhang N. et al. (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3beta signaling pathway. J. Neurochem. 123, 876–885.
23. Gorell J. M., Rybicki B. A., Johnson C. C. and Peterson E. L. (1999) Smoking and Parkinson's disease: a dose-response relationship. Neurology 52, 115–119.
24. Gray R., Ives N., Rick C. et al. (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384, 1196–1205.
25. Hauser R. A., Rascol O., Korczyn A. D., Jon Stoessl A., Watts R. L., Poewe W., De Deyn P. P. and Lang A. E. (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. 22, 2409–2417.
26. Höllerhage M., Goebel J., De Andrade A., Oertel W. H., Hengerer B. and Höglinger G. (2013) Caffeine and nicotine are protective in a new model of a-synuclein mediated cell death in vitro. Basal Ganglia. doi:10.1016/j.baga.2013.01.010.
27. Hong D. P., Fink A. L. and Uversky V. N. (2009) Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim. Biophys. Acta 1794, 282–290.
28. Jung Kang U. and Auinger P. and On behalf of the Parkinson Study Group ELLDOPA Investigators (2012) Activity enhances dopaminergic long-duration response in Parkinson disease. Neurology, 78, 1146–1149.
29. Kalia L. V., Kalia S. K. and Lang A. E. (2015) Disease-modifying strategies for Parkinson's disease. Mov. Disord. 30, 1442–1450.
30. Karpinar D. P., Balija M. B., Kugler S. et al. (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28, 3256–3268.
31. Kieburtz K., Tilley B. C., Elm J. J. et al. (2015) Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313, 584–593.
32. de Lau L. M., Koudstaal P. J., Hofman A. and Breteler M. M. (2005) Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 58, 797–800.
33. Lemay S., Chouinard S., Blanchet P., Masson H., Soland V., Beuter A. and Bedard M. A. (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 31–39.
34. Levin J., Schmidt F., Boehm C., Prix C., Bötzel K., Ryazanov S., Leonov A., Griesinger C. and Giese A. (2014) The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 127, 779–780.
35. Luk K. C., Kehm V. M., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. (2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975–986.
36. Macleod A. D., Taylor K. S. and Counsell C. E. (2014) Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 29, 1615–1622.
37. Mamikonyan E., Xie S. X., Melvin E. and Weintraub D. (2015) Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov. Disord. 30, 912–918.
38. McIntyre C. C. and Anderson R. W. (2016) Deep brain stimulation mechanisms: the control of network activity via neurochemistry modulation. J. Neurochem. 139 (Suppl. 1), 338–345.
39. Miksys S. and Tyndale R. F. (2006) Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J. Neural Transm. Suppl. 70, 177–180.
40. Morais V. A., Haddad D., Craessaerts K. et al. (2014) PINK1 loss of function mutations affect mitochondrial complex I activity via NdufA10 Ubiquinone uncoupling. Science (New York, NY). 344, 203–207.
41. Morens D. M., Grandinetti A., Reed D., White L. R. and Ross G. W. (1995) Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45, 1041–1051.
42. NINDS Exploratory Trials in Parkinson Disease FS-ZONE Investigators (2015) Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795–803.
43. Odekerken V. J., van Laar T., Staal M. J. et al. (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 12, 37–44.
44. Oertel W. H., Wolters E., Sampaio C. et al. (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. 21, 343–353.
45. Olanow C. W., Rascol O., Hauser R. et al. (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278.
46. Olanow C. W., Kieburtz K., Odin P. et al. (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13, 141-149.
47. Olanow C. W., Bartus R. T., Baumann T. L. et al. (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78, 248–257.
48. Pahwa R., Tanner C. M., Hauser R. A. et al. (2016) ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study. Mov. Disord. 31, Suppl. 2, S663, Abstract 2012.
49. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284, 1931–1938.
50. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566.
51. Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62, 241–248.
52. Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch. Neurol. 66, 563–570.
53. Parkinson Study Group DATATOP Investigators (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 321, 1364–1371.
54. Parkinson Study Group DATATOP Investigators (1996a) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol. 39, 37–45.
55. Parkinson Study Group DATATOP Investigators (1996b) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol. 39, 29–36.
56. Parkinson Study Group, Q. E. I., Beal M. F. and Oakes D. et al. (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol, 71, 543–552.
57. Poewe W. (2008) When a Parkinson's disease patient starts to hallucinate. Pract. Neurol. 8, 238–241.
58. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047.
59. Postuma R. B., Lang A. E., Munhoz R. P. et al. (2012) Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 79, 651–658.
60. Quik M. (2004) Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27, 561–568.
61. Quik M., Parameswaran N., McCallum S. E. et al. (2006) Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. 98, 1866–1875.
62. Quik M., O'Leary K. and Tanner C. M. (2008) Nicotine and Parkinson's disease: implications for therapy. Mov. Disord. 23, 1641–1652.
63. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E. and Lang A. E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342, 1484–1491.
64. Rascol O., Brooks D. J., Melamed E., Oertel W., Poewe W., Stocchi F. and Tolosa E. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365, 947–954.
65. Rascol O., Fitzer-Attas C. J., Hauser R. et al. (2011) A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 10, 415–423.
66. Ravina B., Putt M., Siderowf A. et al. (2005) Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry 76, 934–939.
67. Rinne U. K., Bracco F., Chouza C. et al. (1997) Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48, 363–368.
68. Ritz B., Lee P. C., Lassen C. F. and Arah O. A. (2014) Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 83, 1396–1402.
69. Schapira A. H., McDermott M. P., Barone P. et al. (2013) Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 12, 747–755.
70. Schulz J. B. (2012) Effects of selegiline and rasagiline on disease progression in Parkinson's disease. Basal Ganglia 2, S41–S45.
71. Schulz J. B. and Beal M. F. (1994) Mitochondrial dysfunction in movement disorders. Curr. Opin. Neurol. 7, 333–339.
72. Shannon K. M., Bennett J. P., Jr and Friedman J. H. (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 49, 724–728.
73. Stokholm M. G., Danielsen E. H., Hamilton Dutoit S. J. and Borghammer P. (2016) Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79, 940–949.
74. Stuendl A., Kunadt M., Kruse N., Bartels C., Moebius W., Danzer K. M., Mollenhauer B. and Schneider A. (2016) Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain 139, 481–494.
75. Szoke B., Wrasidlo W., Stocking E. et al. (2014) Biophysical characterization of the interaction of NPT200-11 with alpha-synuclein, Program No 411.04/L11. Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2014. Online
76. Tanner C. M., Goldman S. M., Aston D. A., Ottman R., Ellenberg J., Mayeux R. and Langston J. W. (2002) Smoking and Parkinson's disease in twins. Neurology 58, 581–588.
77. Tsukada H., Miyasato K., Harada N., Nishiyama S., Fukumoto D. and Kakiuchi T. (2005) Nicotine modulates dopamine synthesis rate as determined by L-[beta-11C]DOPA: PET studies compared with [11C]raclopride binding in the conscious monkey brain. Synapse 57, 120–122.
78. Vieregge A., Sieberer M., Jacobs H., Hagenah J. M. and Vieregge P. (2001) Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 57, 1032–1035.
79. Vilas D., Iranzo A., Tolosa E. et al. (2016) Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 15, 708–718.
80. Villafane G., Cesaro P., Rialland A., Baloul S., Azimi S., Bourdet C., Le Houezec J., Macquin-Mavier I. and Maison P. (2007) Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur. J. Neurol. 14, 1313–1316.
81. Wagner J., Ryazanov S., Leonov A. et al. (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 125, 795–813.
82. Weisskopf M. G., O'Reilly E., Chen H., Schwarzschild M. A. and Ascherio A. (2007) Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166, 561–567.
83. Wills A. M., Eberly S., Tennis M. et al. (2013) Caffeine consumption and risk of dyskinesia in CALM-PD. Mov. Disord. 28, 380–383.
84. Zhang N., Shu H. Y., Huang T. et al. (2014) Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS ONE 9, e100286.